Grant: CIHR Fellowship
Direct Payment
$150,000.00
Clonal Studies of the JAK2 V617F Mutation in Myeloproliferative Disorders
EF 2008-09
Résumé
The blood system of humans must produce and destroy billions of blood cells on a daily basis in order to keep up with the demands of the body. Sometimes this process is imperfect and incorrect numbers/types of blood cells are produced, resulting in chronic or acute disease. The myeloproliferative disorders (MPDs) are chronic conditions that can be divided into four main types: Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Idiopathic Myelofibrosis (IMF). All are believed to be caused by a mutation, or series of mutations, in a blood stem cell that subsequently gains a growth advantage and causes a disturbance in the numbers of blood cells. In the case of CML, a unique genetic abnormality was identified three decade ago that associates with >95% of CML cases. Subsequent studies were performed that identified a drug that targeted the activity of this protein (Gleevec), which has been one of the most successful targeted therapies in modern medicine. The other MPDs are not helped by this drug, but very recently (2005), a unique genetic mutation was found to associate with many of them. This mutation occurs in the JAK2 protein which, like the BCR-ABL mutation in CML, is a kinase that leads to activation of many proteins in the cell. The reason for the existence of this mutation and the consequences of its presence are poorly understood. This project aims to elucidate the biology of JAK2 mutated cells in samples from one of the world's largest collections of MPD patients (in Cambridge, UK) by studying individual patient samples to look for genes and proteins that are differently expressed in cells with 0, 1, or 2 copies of the mutation. We hope that this work will lead to novel insights about MPD pathogenesis and lead to novel therapeutic targets for the treatment of MPD patients.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
182063
Name
Kent David G
Country
United Kingdom
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Clonal Studies of the JAK2 V617F Mutation in Myeloproliferative Disorders
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Signalling; Colony Assays; Cytokines; Gene Expression; Hematopoiesis; Immuno-Affinity Capillary Electrophoresis; Leukemia; Myeloproliferative Disorders; Primary Cell Culture; Stem Cells
Abstract
The blood system of humans must produce and destroy billions of blood cells on a daily basis in order to keep up with the demands of the body. Sometimes this process is imperfect and incorrect numbers/types of blood cells are produced, resulting in chronic or acute disease. The myeloproliferative disorders (MPDs) are chronic conditions that can be divided into four main types: Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Idiopathic Myelofibrosis (IMF). All are believed to be caused by a mutation, or series of mutations, in a blood stem cell that subsequently gains a growth advantage and causes a disturbance in the numbers of blood cells. In the case of CML, a unique genetic abnormality was identified three decade ago that associates with >95% of CML cases. Subsequent studies were performed that identified a drug that targeted the activity of this protein (Gleevec), which has been one of the most successful targeted therapies in modern medicine. The other MPDs are not helped by this drug, but very recently (2005), a unique genetic mutation was found to associate with many of them. This mutation occurs in the JAK2 protein which, like the BCR-ABL mutation in CML, is a kinase that leads to activation of many proteins in the cell. The reason for the existence of this mutation and the consequences of its presence are poorly understood. This project aims to elucidate the biology of JAK2 mutated cells in samples from one of the world's largest collections of MPD patients (in Cambridge, UK) by studying individual patient samples to look for genes and proteins that are differently expressed in cells with 0, 1, or 2 copies of the mutation. We hope that this work will lead to novel insights about MPD pathogenesis and lead to novel therapeutic targets for the treatment of MPD patients.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kent, David G
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~